Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

The original article contained incorrect terminology for one of the cardiac measures; throughout the manuscript and supplementary information ‘intraventricular septum wall thickness’ should have been given as ‘interventricular septum wall thickness’. Corrections should also be noted for Tables 1 and 4: in the Table 1 legend‘Low risk – Neither above at baseline’ should read‘Low risk – Neither above threshold at baseline’; in Table 4, the rows‘Mild: eGFR> 60 to< 90 ml/min/1.73 m2’ and‘Moderate: eGFR> 30 to< 60 ml/min/1.73 m2’ should read‘Mild: eGFR ≥ 60 to< 90 ml/min/1.73 m2’ and‘Moderate: eGFR ≥ 30 to< 60 ml/min/1.73 m2’, respectively. The original article also contained a mistake in the text of the Pharmacokinetics sub-section of Results;‘There were no apparent differences in revusiran Cmaxbetween patients with mild (eGFR: 30 and< 60 ml/min/1.73 m2)or moderate (eGFR: 60 to< 90 ml/min/1.73 m2)renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m2)renal function at Weeks 0, 26, and 52 (p> 0.20) (Supplementary Fig. 6) ’ should read‘There were no apparent differences in revusiran Cmaxbetween patients with mild (eGFR: ≥ 60 to< 90 ml/min/1.73 m2)or moderate (eGFR: ≥ 30 and< 60 ml/min/1.73 m2)renal impairment when compared with patients with normal (eGFR: ≥ 90 ml/min/1.73 m2)renal function at Weeks 0, 26, and 52 (p> 0.20) (Supplementary Fig. 6) ’.

Source: Cardiovascular Drugs and Therapy - June 15, 2020 Category: Cardiology Source Type: research